Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02333071 · ClinicalTrials.gov registry record · Phase 3
1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
A Phase 3 study, sponsored by Palatin Technologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 723
- Enrollment target
NCT02333071 is a Phase 3 study that has completed, run by Palatin Technologies. The registered enrollment target is 723 participants.
The verdict
NCT02333071, a Phase 3 study, has completed, sponsored by Palatin Technologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 723 participants
- Enrollment target
Study Summary
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without decreased arousal) in premenopausal females.
Interventions
- OTHER Placebo
- DRUG Bremelanotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 723 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02333071
The ClinicalTrials.gov registry entry for NCT02333071 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 723 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Palatin Technologies, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02333071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02333071 about?
NCT02333071 is a clinical study titled "1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder". A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the treatment of HSDD (with or without decreased arousal) in premenopausal f...
What is the current status of trial NCT02333071?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 723 participants. The study started on 2014-12. Estimated completion is 2017-06-30.
What interventions are being tested in trial NCT02333071?
The interventions under investigation include: Placebo (OTHER), Bremelanotide (DRUG).
Who is sponsoring clinical trial NCT02333071?
This trial is sponsored by Palatin Technologies, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.